|
Results of Search
| BCRJ: | 0022 | | Cell Line: | 4T1 | | Tissue: | | | Organ: | MAMARIAN GLAND | | Cell Type: | B LYMPHOCYTE | | Morphology: | EPITHELIAL | | Pathology: | TUMOR | | Scientific Name: | MUS MUSCULUS | | Vulgar Name: | MOUSE | | Sex: | | | Miscelaneous Info: | | | Virus Succeptibility: | | | Virus Resistance: | | | Tumor Formation: | YES | | Products: | | | Dependency Isoenzymes: | | | Culture Medium: | The base medium for this cell line is RPMI-1640 Medium. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing: NOTE: the cells should not be allowed to become confluent, subculture at 80% of confluence. Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation Ratio: A subcultivation ratio of 1:6 to 1:8 is recommended
Medium Renewal: Every 2 to 3 days
Storage temperature: liquid nitrogen vapor temperature | | Consigner: | LUIS RODOLPHO TRAVASSOS
UNIDADE DE ONCOLOGIA EXPERIMENTAL
UNIFESP | | Reference: | 49687: Pulaski BA, et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol. Immunother. 49: 34-45, 2000. PubMed: 10782864
49688: Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493, 1998. PubMed: 9537252
49689: Pulaski BA, et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 60: 2710-2715, 2000. PubMed: 10825145
49690: Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405, 1992. PubMed: 1540948 | | Additional Info: | 4T1 is a 6-thioguanine resistant cell line selected from the 410.4 tumor without mutagen treatment. [49690]
When injected into BALB/c mice, 4T1 spontaneously produces highly metastatic tumors that can metastasize to the lung, liver, lymph nodes and brain while the primary tumor is growing in situ. [49688] [49690]
The primary tumor does not have to be removed to induce metastatic growth.
The tumor growth and metastatic spread of 4T1 cells in BALB/c mice very closely mimic human breast cancer. This tumor is an animal model for stage IV human breast cancer. [49688] [49689]
4T1-induced tumors can be used as a post-operative model as well as a non-surgical model because the 4T1-induced tumor metastasizes spontaneously in both models with similar kinetics. [49687] [49688] [49689]
Because 4T1 is resistant to 6-thioquanine, micro-metastatic cells (as few as 1) can be detected in many distant site organs with better accuracy that most tumor models. There is no need to count nodules or weight target organs. [49687] [49688] [49689] | | ATCC: | CRL-2539 | | Biosafety: | 1 |
|
